Kymera Therapeutics, Inc.
KYMR
Ранг среди акций
#2168
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Цена акции
$114.80
Рыночная капитализация
$9.44B
Изменение (1 день)
1.18%
Изменение (1 год)
96.84%
Страна
US
Торговля Kymera Therapeutics, Inc. (KYMR)
Категория
Healthcare
Выручка компании Kymera Therapeutics, Inc. (KYMR)
Выручка на Jun 2026 TTM: $104.99M
Согласно последним финансовым отчетам Kymera Therapeutics, Inc., текущая выручка компании (TTM) составляет $104.99M. В 2023 году компания получила выручку $78.59M больше, чем выручке в 2022 году, которая составила $46.83M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Kymera Therapeutics, Inc. с 2018 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $104.99M | 123.04% |
| 2024 | $47.07M | -40.11% |
| 2023 | $78.59M | 67.84% |
| 2022 | $46.83M | -35.71% |
| 2021 | $72.83M | 114.00% |
| 2020 | $34.03M | 1,059.99% |
| 2019 | $2.93M | 0.00% |
| 2018 | 0.00 | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $12.62B | 11,924.40% |
US
|
|
| $2.23B | 2,022.13% |
US
|
|
| $15.74B | 14,896.17% |
AU
|
|
| $6.02B | 5,635.16% |
NL
|
|
| - | - |
CH
|
